Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.

Key Points

• Pacer Advisors cut its Charles River Laboratories stake by 98.4% in the first quarter, selling 151,431 shares and retaining 2,454 shares worth approximately $423,000.
• Analyst sentiment remains favorable: 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, resulting in a consensus “Moderate Buy” rating and a $255.65 average price target.
• Recent results beat expectations, but revenue declined year over year. Quarterly adjusted EPS was $3.02 versus the $2.77 consensus, while revenue reached about $1 billion, down 2.7% from the prior year; insiders also sold roughly $28.9 million of stock during the last quarter.

Pacer Advisors Inc. lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 98.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,454 shares of the medical research company's stock after selling 151,431 shares during the quarter. Pacer Advisors Inc.'s holdings in Charles River Laboratories International were worth $423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp boosted its stake in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock valued at $253,000 after buying an additional 1,074 shares in the last quarter. Empowered Funds LLC purchased a new position in Charles River Laboratories International in the first quarter worth $418,000. American Century Companies Inc. lifted its holdings in Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company's stock valued at $830,000 after acquiring an additional 1,616 shares during the period. Brown Advisory Inc. lifted its holdings in Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company's stock valued at $354,000 after acquiring an additional 114 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company's stock worth $12,837,000 after purchasing an additional 3,198 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CRL shares. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Morgan Stanley upped their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an "overweight" rating in a research report on Friday. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Citigroup reissued a "buy" rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $255.65.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analyst support remains favorable. Piper Sandler set a $300 price target, while Barclays maintained an overweight rating and a $300 target. RBC also raised its target to $282 and reiterated an outperform rating. Overall, 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Given Consensus Rating of Moderate Buy
• Positive Sentiment: Recent operating results exceeded expectations. Charles River reported quarterly adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15 to $11.45 per share.
• Positive Sentiment: Strong momentum has attracted attention. CRL reached a new 52-week high near $277, with trading volume above its average. The stock is also well above its 50-day and 200-day moving averages, indicating continued technical momentum. Charles River Laboratories International Sets New 52-Week High
• Neutral Sentiment: International-market exposure remains an investor focus. A recent analysis examines how Charles River’s international revenue trends could affect Wall Street forecasts and the stock’s outlook, but the provided report does not identify a specific estimate change. International Markets and Charles River Deep Dive
• Negative Sentiment: Several insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer sold 4,179 shares worth about $1.1 million, and CAO Michael Gunnar Knell sold 6,645 shares worth approximately $1.7 million. These planned transactions may raise caution, although they do not necessarily signal deteriorating business prospects. SEC insider transaction filing

Insider Buying and Selling at Charles River Laboratories International

In related news, CAO Michael Gunnar Knell sold 6,645 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at $3,086,023.76. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Shannon M. Parisotto sold 5,046 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,264,241. The trade was a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 119,603 shares of company stock valued at $28,916,928. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $281.70 on Wednesday. The firm has a market capitalization of $13.45 billion, a PE ratio of -58.08, a P/E/G ratio of 2.87 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $282.39. The firm's 50-day simple moving average is $218.88 and its 200 day simple moving average is $189.84. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the firm posted $3.12 EPS. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.34 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source